AB0816 CARDIOVASCULAR COMORBIDITIES IN PSORIATIC ARTHRITIS: A CASE CONTROL STUDY.
Authors: D. Á. Galarza-Delgado, J. R. Azpiri-López, I. J. Colunga-Pedraza, A. Pérez Villar, I. C. Zárate Salinas, P. F. Frausto Lerma, M. A. Reyes Soto, D. E. Flores Alvarado, O. Ilizaliturri Guerra
Journal: Annals of the Rheumatic Diseases (2020)

Background: Psoriatic Arthritis (PsA) is an inflammatory arthritis associated with psoriasis. It occurs in approximately 8% –30% of patients diagnosed with psoriasis. In addition to joint and skin manifestations, patients with PsA have an increased prevalence of traditional cardiovascular (CV) risk factors that has been associated with a higher severity of PsA and increased cardiovascular disease (CVD). However, this increased risk has been attributed not only to increased traditional risk factors but also to chronic systemic inflammation. Objectives: To compare the most relevant CV comorbidities in patients with PsA and controls. Methods: A cross-sectional observational study was designed, 94 patients between 45-75 years who fulfilled the CASPAR classification criteria for PsA and 94 age-matched controls were included. The clinical characteristics compared between groups were: age, BMI, waist/hip index, gender, diabetes mellitus, hypertension, dyslipidemia, overweight, obesity, smoking history and prior cardiovascular event. Student-t test, Mann-Whitney U, Chi 2 test and Fisher’s exact test were used to compare data and odds ratio were calculated. p ≤ 0.05 was considered statistically significant. Logistic regression analysis was used to test association between significant clinical risk factors for PsA. The data were analyzed using the SPSS version 25 software. Results: 94 PsA patients and 94 controls were included. The majority of the patients were women (57.4% in the PsA group and 80.9% in the control group) ( p 0.001). Body mass index and waist/hip index were higher in PsA group ( p 0.002) ( p &lt;0.001) respectively. PsA patients had more hypertension than controls ( p 0.022), more overweight ( p 0.005), and a higher smoking history ( p &lt;0.001) than the control group. There was a trend in higher hyperlipidemia prevalence in PsA patients (Table 1). Table 1. Clinical comorbidities and risk factors for PsA. Variable PsA Control p OR (95% CI) Age* 53.23 ± 11.31 53 ± 10 0.790 BMI* 29.37 ± 5.32 27.21 ± 4.17 0.002 Waist/Hip Index** 0.94 (0.88-1.03) 0.90 (0.85-0.92) &lt;0.001 Gender 0.001 Female 54 (57.4%) 76 (80.9%) Male 40 (42.6%) 18 (19.1%) Diabetes 18 (19.1%) 14 (14.9%) 0.438 1.35 (0.62-2.91) Hypertension 33 (35.1%) 19 (20.2%) 0.022 2.13 (1.10-4.12) Dyslipidemia 36 (38.3%) 24 (25.5%) 0.06 1.81 (0.97-3.37) Overweight 77 (81.9%) 60 (63.8%) 0.005 2.56 (1.31-5.03) Obesity 36 (37.6%) 26 (27.7%) 0.146 1.57 (0.85-2.92) Smoking history 36 (38.3%) 78 (83%) &lt;0.001 0.127 (0.06-0.25) History of CVD 68 (72.3%) 8 (53.3%) 0.137 2.28 (0.75-6.94) *Data are reported in mean ± SD **Data is reported in median (IQR) We performed a multivariate analysis that showed that being overweight and presenting a waist / hip index above 0.90 cm confers an increased risk of developing PsA (Table 2). Table 2. Multivariate analysis of significant clinical risk factors for PsA. Variable p OR (95% CI ) Hypertension 0.239 1.69 (0.70-4.05) Overweight 0.027 2.57 (1.11-5.92) Waist/hip index &gt;0.90 0.007 2.80 (1.32-5.95) Conclusion: Several traditional cardiovascular risk factors were found with a higher prevalence in the group with psoriasis. It is critical that physicians known the common comorbidities associated with PsA so that they can provide optimal management and treatment and improve mortality and quality of life. References: [1]Husni, M. E. (2015). Comorbidities in psoriatic arthritis. Rheumatic Disease Clinics, 41(4), 677-698. Disclosure of Interests: None declared